

## OHSU Diagnostic Imaging Services The Breast Center at OHSU

**Scheduling:** 503-494-4673 **Fax:** 503-418-8980 Patient must call 503-494-4673 to schedule

REQUIRED INFORMATION								
Patient Name:								
<b>Patient Pho</b>	ne:			Date of B	irth:	/	1	
Can the patient stand unsupported for 20 minutes? ☐ YES ☐ NO								
Reason for Exam:								
ICD 10 Code					Authoriz	zation #:		
REFERRING PROVIDER INFORMATION								
Referring Provider:				Phone:				
Signature:				Date:	/			
☐ I authorize study specific medications, lab work and additional imaging procedures per the OHSU department standard.								
EXAM	FOCUS							
Screening Mammogram	For asymptomatic patients ≥ 40 years, high risk, or history of breast cancer more than 5 years prior.							
	☐ Left		□ WITH IMPLANTS			IMPLANT	_	
	•		☐ 3D Tomosynthesis with C		•			
	☐ Bilateral (high risk, dense tissue, history breast disease) (Computer-Aided Detection)  All screening mammograms are reviewed by CAD technology on an annual basis.							
	□ Left		WITH IMPLANTS					
Diagnostic Mammogram			3D Tomosynthesis (short term				add views)	
	•		3D Tomosynthesis with CAD (a	•	•		•	
	If pt. has a new lump, nipple discharge, or focal pain, also order a breast ultrasound.							
	Consider 3D Tomosynthesis for high risk, dense tissue, history breast disease.							
Ultrasound	□ US Breast Left □ US Breast Right □ US Breast Bilateral							
Breast	If pt. is $\geq$ 35 years and has: new lump, nipple discharge, focal pain, <b>also order a Diagnostic Mammogran</b>							
Axilla	☐ US Breast Density Screening Bilateral ☐ US Axilla Left ☐ US Axilla Rig						t	
MRI Breast	☐ With	and Witho	ut Contrast Bilateral		Order oral	medications	for	
	☐ Without Contrast Bilateral (for silicone implant evaluation) patient pick up at pharmacy if							
	First day of last menses:/							
Biopsy	☐ Left	☐ Right	Stereotactic Breast Biopsy	and Lab: Sur	gical Pathol	logy		
	□ Left	☐ Right	US Breast Core Biopsy	and Lab: Sur	gical Pathol	logy		
	□ Left	☐ Right	MRI Breast Core Biopsy	and Lab: Sur	gical Pathol	logy		
	☐ Left	□ Right	US Axilla Core Biopsy	and Lab: Sur	gical Pathol	logy		
FNA	☐ Left	☐ Right	US Axilla FNA and Lab: F	ine Needle Asp	irate			
Aspiration	☐ Left	☐ Right	US Breast FNA and Lab: F	ine Needle Asp	irate			
	☐ Left	☐ Right US Breast Fluid Aspiration and Lab: Culture, Wound Abscess or Aspirate						
Ductogram	☐ Left	☐ Right	Ductogram					
Other:			<del>-</del>					
Specify								
Patient Instru	CTIONS	L)O not w	ear nowder deodorant ne	rtume or lotio	n			

OHSU Department Standard:						
At the discretion of the radiologist, the following unilateral or bilateral exams may be performed.						
Screening	For asymptomatic patients 40 years of age or greater, high risk screening, or for a history of					
Mammogram	breast cancer more than 5 years prior.  For patients at high risk for breast cancer, annual screening mammography may commence at					
	age 30 (or as specified in the scenarios below). This includes:					
	Known genetic mutation or syndrome conferring increased breast cancer risk.					
	No genetic testing but has a first-degree relative with a BRCA mutation.					
	A 20% or greater lifetime risk for breast cancer based on breast cancer risk model(s).					
	A first-degree relative with breast cancer may commence screening 10 years earlier than the					
	age at which the youngest first-degree relative was diagnosed (but not before age 30).					
	A history of chest (mantle) radiation received between the ages of 10 and 30 should begin					
	screening 8 years after the radiation therapy, (but not before age 25). Biopsy-proven lobular					
	neoplasia or atypical ductal hyperplasia and ductal carcinoma in situ, invasive breast cancer, or					
	ovarian cancer should begin mammography at the time of diagnosis, regardless of age.					
Diagnostic	Performed for evaluation of the following:					
Mammogram	Patient is symptomatic: has a new lump/area of palpable concern, a persistent focal area of pain					
	or tenderness, skin/nipple changes or nipple discharge.					
	Patient has a history of breast cancer less than 5 years prior.					
	Evaluation of abnormal imaging findings identified on screening mammography.					
	Characterization of findings noted on imaging exams not specific to the breast (e.g. CT, MRI).					
	Follow-up eval of a mammographic finding assessed as "probably benign" at prior diagnostic					
	exam, as defined by the ACR Breast Imaging Reporting and Data System (BI-RADS®).					
DBT	Initial imaging: Age greater than or equal to 35.  Digital Breast Tomosynthesis/3D Tomosynthesis: Will be done at the patient's request.					
US Breast	Patient is symptomatic: has a new lump/area of palpable concern, a persistent focal area of pain					
US Bleast	or tenderness, skin/nipple changes or nipple discharge, history of breast cancer less than 5					
	years prior. Evaluation of problems associated with breast implants.					
	Initial imaging: Any age (less than 30, 30-39, > 40).					
US Breast Density	Performed to define the visually estimated content of fibroglandular-density tissue within the					
Screening	breasts as additional screening with mammography for dense breast tissue.					
US Breast FNA	Performed for suspected abnormal lesion for the purpose of obtaining sufficient tissue/cells to					
	establish a pathologic diagnosis or to guide appropriate patient management.					
US Breast Fluid	Performed for cyst, abscess, or seroma fluid characterization.					
Aspiration	Performed for therapeutic drainage.					
US Breast Biopsy:	Performed for complex cystic and solid masses, microcalcifications, asymmetries, and					
Core or Vacuum	architectural distortions:					
Assisted	May be performed in conjunction with marker/clip placement.					
Stereotactic Breast	Performed for mammographically depicted findings, that are not well seen or identified with					
Biopsy: Vacuum	ultrasound guidance. May be performed in conjunction with marker/clip placement.					
US Axilla R/L	Performed to evaluate abnormal imaging findings on breast ultrasound or mammography.					
US Axilla FNA	Performed for histopathologic proof of axillary nodal involvement, abnormal-appearing nodes, or					
	axillary involvement in clinically node-negative patients.					
	Performed to evaluate suspected abnormal lesions for the purpose of obtaining sufficient					
	tissue/cells to establish a pathologic diagnosis or to guide appropriate patient management.					
US Axilla Core	Performed when the suspicion of malignancy is high and if abnormal lymph nodes are seen					
Biopsy	within the axilla or axillary tail. May be performed at the time of initial imaging-guided core					
Duotogram	biopsy of a suspicious breast mass or at a later time.					
Ductogram	Performed for evaluation of pathologic nipple discharge.					
Lab Work:	Culture, Wound Abscess or Aspirate; Gram Smear routinely performed by Lab services, Sensitivity if indicated by results. FNA Fine Needle Aspirate, Surgical Pathology					
Medications	9 mL Lidocaine HCl 1%, 10 mg/ml, 1 mL Sodium Bicarbonate 8.4%, 1 mEq/mL. Local.					
	Lidocaine 1% and Epinephrine 1:100,111. Local anesthetic. Lidocaine and Prilocaine Cream					
	2.5%/2.5%. Local anesthetic. 300mg/ml Omnipaque, 1mL. For ductogram.					
	Spot Endoscopic tattoo ink. Marker Dye. Methylene blue. Marker dye.					